Combination of docetaxel, trastuzumab and pertuzumab or treatment with trastuzumab-emtansine for metastatic salivary duct carcinoma-Reference-Cited by-同舟云学术

Combination of docetaxel, trastuzumab and pertuzumab or treatment with trastuzumab-emtansine for metastatic salivary duct carcinoma

Published:2017-09 Issue: Volume:72 Page:198-200
ISSN:1368-8375
Container-title:Oral Oncology
language:en
Short-container-title:Oral Oncology

Author:

van Boxtel Wim,Boon Eline,Weijs Willem L.J.,van den Hoogen Frank J.A.,Flucke Uta E.,van Herpen Carla M.L.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Oral Surgery

Reference16 articles.

1. Systemic therapy in metastatic salivary gland carcinomas: a pathology-driven paradigm?;Alfieri;Oral Oncol,2017

2. Clinical and immunohistologic typing of salivary duct carcinoma: a report of 50 cases;Jaehne;Cancer,2005

3. A 20-year review of 75 cases of salivary duct Carcinoma;Gilbert;JAMA Otolaryngol. Head Neck Surg.,2016

4. Boon E, Bel E, van Boxtel W, et al. Salivary duct carcinoma an analysis of clinical outcome, AR and HER-2 expression and prognostic factors of 177 patients from the Netherlands. Unpublished results.

5. Unmet needs for patients with salivary gland cancer;Dunn;Oral Oncol.,2016

Cited by 35 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. HER2-targeted therapies for salivary gland cancers;Oral Oncology;2024-01

2. Systemic therapies for salivary gland carcinoma (excluding adenoid cystic carcinoma): REFCOR recommendations by the formal consensus method;European Annals of Otorhinolaryngology, Head and Neck Diseases;2023-11

3. Targeting human EGFR 2 (HER2) in salivary gland carcinoma;Expert Review of Anticancer Therapy;2023-05-16

4. Role of HER2 in Prognosis of Salivary Duct Carcinoma: A Systematic Review and Meta‐Analysis;The Laryngoscope;2022-05-14

5. The Role of the EZH2 and H3K27me3 Expression as a Predictor of Clinical Outcomes in Salivary Duct Carcinoma Patients: A Large-Series Study With Emphasis on the Relevance to the Combined Androgen Blockade and HER2-Targeted Therapy;Frontiers in Oncology;2022-02-03